Filters: author is Mandema [Clear All Filters]
- 1999
Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam,
J Pharmacol Exp Ther, vol. 289, no. 2, pp. 1067-74.
- 1998
Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam,
J Pharmacol Exp Ther, vol. 284, no. 1, pp. 202-7.
Pharmacokinetic-pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats,
J Pharmacol Exp Ther, vol. 284, no. 2, pp. 460-6.
- 1997
Determination of dexmedetomidine in rat plasma by a sensitive [3H]clonidine radioreceptor assay,
J Pharm Sci, vol. 86, no. 7, pp. 822-6. DOI
The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates,
J Pharmacokinet Biopharm, vol. 25, no. 1, pp. 39-62.
Pharmacokinetic-pharmacodynamic characterization of the cardiovascular, hypnotic, EEG and ventilatory responses to dexmedetomidine in the rat,
J Pharmacol Exp Ther, vol. 283, no. 3, pp. 1051-8.
- 1996
Pharmacokinetic/pharmacodynamic relationship of benzodiazepines in the direct cortical stimulation model of anticonvulsant effect,
J Pharmacol Exp Ther, vol. 279, no. 2, pp. 803-12.
- 1995
Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain,
Br J Pharmacol, vol. 116, no. 5, pp. 2538-44.
Pharmacodynamic interaction between midazolam and a low dose of ethanol in vivo,
Life Sci, vol. 57, no. 4, pp. 325-33. DOI
- 1993
Pharmacokinetic-pharmacodynamic modelling in pre-clinical investigations: principles and perspectives,
Eur J Drug Metab Pharmacokinet, vol. 18, no. 1, pp. 41-7.
A comparison of the concentration-effect relationships of midazolam for EEG-derived parameters and saccadic peak velocity,
Br J Clin Pharmacol, vol. 36, no. 2, pp. 109-15.
- 1992
Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs,
Clin Pharmacokinet, vol. 23, no. 3, pp. 191-215.
Pharmacokinetic-EEG effect relationship of midazolam in aging BN/BiRij rats,
Br J Pharmacol, vol. 107, no. 1, pp. 171-7.
Modelling of the pharmacodynamics and pharmacodynamic interactions of CNS active drugs,
Int J Clin Pharmacol Ther Toxicol, vol. 30, no. 11, pp. 516-9.
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers,
Clin Pharmacol Ther, vol. 51, no. 6, pp. 715-28.
Differences in intrinsic efficacy of benzodiazepines are reflected in their concentration-EEG effect relationship,
Br J Pharmacol, vol. 105, no. 1, pp. 164-70.
In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil,
J Pharmacol Exp Ther, vol. 260, no. 1, pp. 36-44.
In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy,
J Pharmacol Exp Ther, vol. 261, no. 1, pp. 56-61.
Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures,
J Pharmacol Exp Ther, vol. 261, no. 1, pp. 88-95.
- 1991
Biophase equilibration times,
J Pharm Sci, vol. 80, no. 9, pp. 881-6.
A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat,
J Pharmacokinet Biopharm, vol. 19, no. 5, pp. 485-96.
A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling,
J Pharm Sci, vol. 80, no. 5, pp. 488-95.
Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration,
Br J Pharmacol, vol. 102, no. 3, pp. 663-8.
Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions,
J Pharmacokinet Biopharm, vol. 19, no. 6, pp. 617-34.
Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity,
J Pharmacol Exp Ther, vol. 257, no. 1, pp. 472-8.


